Q BioMed Inc. (QBIO)

Market Cap	145.00 -99.8%
Revenue (ttm)	209.29K -22.7%
Net Income	-1.91M
EPS	-0.03
Shares Out	145.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	23,423
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0000 - 0.0251
Beta	181.13
RSI	45.81
Earnings Date	n/a

About Q BioMed

Q BioMed Inc. engages in the acquisition, development, and financing of biomedical assets. The company offers Strontium Chloride Sr-89/Metastron, a radiopharmaceutical for the treatment of metastatic cancer bone pain. It also develops various preclinical candidates comprising QBM-001 for rare pediatric non-verbal autism spectrum disorder; UTTROSIDE-B, a chemotherapeutic for liver cancer; and MAN-01, a topical eyedrops for glaucoma. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: QBIO

Financial Performance

In fiscal year 2022, Q BioMed's revenue was $284,352, an increase of 45.38% compared to the previous year's $195,597. Losses were -$3.49 million, -60.03% less than in 2021.